Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-lactating, non-pregnant female subjects who are 40 years or older at the time of initial dosing~  --Physical status within normal limits for age and consistent with observations at Screening~* Able to understand and comply with study procedures required and able and willing to provide written informed consent prior to any study procedures being performed~Exclusion Criteria:~* History of hypersensitivity, allergy or intolerance to omeprazole or other proton-pump inhibitors (PPIs)~* History of hypersensitivity, allergy or intolerance to aspirin or any NSAID and/or a history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps~* History of hypersensitivity or intolerance to clopidogrel~* History of hepatitis B or C, a positive test for hepatitis B surface antigen, hepatitis C antibody, a history of human immunodeficiency virus (HIV) infection or demonstration of HIV antibodies~* History of malignancy, treated or untreated, within the past five years, with the exception of successfully treated basal cell or squamous cell carcinoma of -Evidence of uncontrolled, or unstable cardio- or cerebrovascular disorder, which in the Investigator's opinion, would endanger a subject if he/she were to participate in the study~* Presence of an uncontrolled acute, or a chronic medical illness, e.g., GI disorder, diabetes, hypertension, thyroid disorder, bleeding disorder, infection, which in the Investigator's opinion would endanger a subject if he/she were to participate in the study or interfere with the objective of this study~* Schizophrenia or bipolar disorder~* GI disorder or surgery leading to impaired drug absorption~* \< 70% platelet aggregation at Screening~* Donation of blood or plasma within 4 weeks of the study~* PPI use or any enzyme inducing/inhibiting agents within 4 weeks prior to dosing~* Taking any antiplatelet drug within 2 weeks of the screening visit or during the study, or more than two 325 mg doses of aspirin or more than 2 doses of any other NSAIDs within 14 days prior to the screening visit

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Clopidogrel (Plavix®) and PA32540 (Type: EXPERIMENTAL): PA32540 and Clopidogrel (Plavix®) tablet, 10 hours post PA32540
- EC aspirin, EC omeprazole, Clopidogrel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).